Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2013 | case report | Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2013
Autoren:
Cathrin Skrabs, Christian Sillaber, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Thomas Staudinger, Monique Putman, Werner Rabitsch, Ulrich Jaeger

Abstract

Background

Patients with follicular lymphoma ineligible for standard treatment with the anti-CD20 antibody rituximab represent a considerable challenge as they require alternative therapeutic approaches.

Patient and methods

We describe a patient who experienced a severe episode of serum sickness. Antichimeric antibodies against rituximab were verified in an early stage of disease, rendering further use of the drug impossible. After five treatment lines he developed progressive follicular lymphoma with skin involvement, which was treated with lenalidomide monotherapy.

Results

Six cycles of lenalidomide monotherapy (25 mg orally for 21 days, 1 week off) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalidomide in follicular lymphoma are reviewed.

Conclusion

As shown here, single-agent lenalidomide represent a therapeutic option for pretreated patients with follicular lymphoma ineligible for rituximab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013Zur Ausgabe